Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders

Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders ORIGINAL ARTICLE Long-Chain -3 Fatty Acids for Indicated Prevention of Psychotic Disorders A Randomized, Placebo-Controlled Trial G. Paul Amminger, MD; Miriam R. Schäfer, MD; Konstantinos Papageorgiou, MD; Claudia M. Klier, MD; Sue M. Cotton, PhD; Susan M. Harrigan, MSc; Andrew Mackinnon, PhD; Patrick D. McGorry, MD, PhD; Gregor E. Berger, MD Context: The use of antipsychotic medication for the Main Outcome Measures: The primary outcome mea- sure was transition to psychotic disorder. Secondary out- prevention of psychotic disorders is controversial. Long- comes included symptomatic and functional changes. The chain-3 (omega-3) polyunsaturated fatty acids (PUFAs) ratio of -6 to -3 fatty acids in erythrocytes was used to may be beneficial in a range of psychiatric conditions, index pretreatment vs posttreatment fatty acid composition. including schizophrenia. Given that -3 PUFAs are gen- erally beneficial to health and without clinically rel- Results: Seventy-six of 81 participants (93.8%) com- evant adverse effects, their preventive use in psychosis pleted the intervention. By study’s end (12 months), 2 merits investigation. of 41 individuals (4.9%) in the -3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psy- Objective: To determine whether -3 PUFAs reduce chotic disorder (P = .007). The difference http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Loading next page...
 
/lp/american-medical-association/long-chain-3-fatty-acids-for-indicated-prevention-of-psychotic-B7W39q0NmQ
Publisher
American Medical Association
Copyright
Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/archgenpsychiatry.2009.192
pmid
20124114
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Long-Chain -3 Fatty Acids for Indicated Prevention of Psychotic Disorders A Randomized, Placebo-Controlled Trial G. Paul Amminger, MD; Miriam R. Schäfer, MD; Konstantinos Papageorgiou, MD; Claudia M. Klier, MD; Sue M. Cotton, PhD; Susan M. Harrigan, MSc; Andrew Mackinnon, PhD; Patrick D. McGorry, MD, PhD; Gregor E. Berger, MD Context: The use of antipsychotic medication for the Main Outcome Measures: The primary outcome mea- sure was transition to psychotic disorder. Secondary out- prevention of psychotic disorders is controversial. Long- comes included symptomatic and functional changes. The chain-3 (omega-3) polyunsaturated fatty acids (PUFAs) ratio of -6 to -3 fatty acids in erythrocytes was used to may be beneficial in a range of psychiatric conditions, index pretreatment vs posttreatment fatty acid composition. including schizophrenia. Given that -3 PUFAs are gen- erally beneficial to health and without clinically rel- Results: Seventy-six of 81 participants (93.8%) com- evant adverse effects, their preventive use in psychosis pleted the intervention. By study’s end (12 months), 2 merits investigation. of 41 individuals (4.9%) in the -3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psy- Objective: To determine whether -3 PUFAs reduce chotic disorder (P = .007). The difference

Journal

JAMA PsychiatryAmerican Medical Association

Published: Feb 1, 2010

References